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Abstract
Amyloidosis is an infiltrative disease caused by extracellular protein deposition 
that has accumulated a lot of scientific production in recent years. Different types 
of amyloidosis can affect the heart. Transthyretin amyloidosis and light chain 
amyloidosis are the two most common types of cardiac amyloidosis. These 
entities have a poor prognosis, so accurate diagnostic techniques are imperative 
for determining an early therapeutic approach. Recent advances in cardiac 
imaging and diagnostic strategies show that these tools are safe and can avoid the 
use of invasive diagnostic techniques to histological confirmation, such as 
endomyocardial biopsy. We performed a review on the diagnostic and prognostic 
implications of different cardiac imaging techniques in cardiac amyloidosis. We 
mainly focus on reviewing echocardiography, cardiac magnetic resonance, 
computed tomography and nuclear imaging techniques and the different safety 
measurements that can be done with each of them.
Key Words: Cardiac imaging techniques; Transthyretin cardiac amyloidosis; 
Immunoglobulin light-chain amyloidosis; Echocardiography; Magnetic resonance 
imaging; Nuclear imaging
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Core Tip: Cardiac amyloidosis is a disease with a poor prognosis. However, in recent 
years, specific therapies have been developed. When implemented in the early stages 
of the disease, they are associated with an improvement in the quality of life and 
survival. The use of cardiac magnetic resonance, echocardiography, computed 
tomography and nuclear imaging techniques allows an early diagnosis. In this review, 
we define in detail the implication of each imaging technique in cardiac amyloidosis.
Citation: Vidal-Perez R, Vázquez-García R, Barge-Caballero G, Bouzas-Mosquera A, Soler-
Fernandez R, Larrañaga-Moreira JM, Crespo-Leiro MG, Vazquez-Rodriguez JM. Diagnostic 





Amyloidosis is a systemic infiltrative disease characterized by extracellular amyloid 
deposition, which causes a structural and functional alteration at different organs. 
Amyloid comes from up to 30 different types of misfolded precursor proteins. Only 
five directly affect the heart: Light chain, transthyretin, apolipoprotein A, fibrinogen 
and serum amyloid-protein A; Although, most cases of cardiac amyloidosis (CA) will 
be caused by the first two proteins[1]. The different proteins involved allow classifying 
the different types of amyloidosis, which have different clinical expression, prognosis 
and treatment.
Light chain amyloidosis (AL) is a plasma cell dyscrasia characterized by 
inappropriate production of only one type of light chain. Deposition of these proteins 
can be evidenced not only in the heart but also in the kidneys, nervous system, 
gastrointestinal system and soft tissues[2].
Transthyretin amyloidosis (ATTR) originates from the accumulation of transthyretin 
(a transporter molecule for thyroxine and retinol-bound protein) that mainly comes 
from the liver and whose principal deposit is limited to cardiac tissue, soft tissues and 
the nervous system[3]. Within this type of amyloidosis, two subtypes are classified 
based on the presence or absence of a mutation in the transthyretin gene: Variant 
transthyretin amyloidosis (ATTRv) and wild-type transthyretin amyloidosis 
(ATTRwt).
The early diagnosis of this pathology is essential due to its worse prognosis when it 
affects the heart and the existence of treatments that can modify the evolution of these 
patients[4].
This review aims to describe the different imaging tools for CA diagnosis and the 
prognostic value of the different approaches.
EPIDEMIOLOGY
For years, AL has been considered the most frequent subtype of amyloidosis. 
However, an increase in ATTR diagnoses has been evidenced recently. The incidence 
of AL is estimated to be around three to five patients per million per year[5]. The overall 
prevalence of ATTRv is around 5000–10000 persons, although it is endemic in areas 
such as Portugal, Sweden or specific areas of Japan[6]. The controversy started when 
trying to define the prevalence of ATTRwt. Classically it was considered a rare disease; 
however, a prevalence of 16% has been observed in patients with severe aortic stenosis 
undergoing transcatheter aortic valve replacement[7], 13.3% in patients hospitalized 
with heart failure with preserved ejection fraction and left ventricular hypertrophy 
(LVH) greater than or equal to 12 mm[8] and up to 25% in autopsies of patients > 85 
years[9]. These results imply that it is an underdiagnosed disease, especially in older 
people.
Both subtypes show high morbidity and mortality in the short term. For ATTR-CA, 
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the TRACS study found a median survival from diagnosis of 25.6 mo for ATTRv and 
43.0 mo for ATTRwt[10]. Likewise, cardiac involvement in AL (found in up to 50%-70% 
of patients[11]) determines a worse prognosis with a median survival of 6 mo in patients 
with heart failure and untreated disease[12,13].
CLINICAL MANIFESTATIONS AND DIAGNOSIS
Amyloid can infiltrate any cardiac structure. Mainly, the deposit occurs in both 
ventricular walls increasing wall thickness, progressively altering the ventricular 
compliance and generating diastolic dysfunction. Also, amyloid can infiltrate the atrial 
walls, heart valves and conduction tissue. Clinically it can manifest as heart failure, 
cardiac conduction alteration, valve dysfunctions or with supraventricular 
arrhythmias such as atrial fibrillation.
As previously exposed, CA is a systemic disease that can involve multiple organs. 
ATTR-CA can cause glaucoma due to eye protein deposition. In the nervous system it 
causes varying degrees of ascending symmetric sensory-motor polyneuropathy 
(mainly ATTRv) and sometimes affecting the autonomic nervous system causing 
dysautonomia with orthostatic hypotension, erectile dysfunction, urinary incontinence 
and gastrointestinal symptoms. A greater predisposition to deposit protein in soft 
tissues frequently causing carpal tunnel syndrome (even bilateral), lumbar canal 
stenosis due to deposit in the yellow ligament, atraumatic rupture of the biceps tendon 
(Popeye’s sign on physical examination), quadriceps tendon rupture and Dupuytren’s 
contracture[1,3] has been observed in ATTRwt.
The deposits of the monoclonal protein in LA can affect not only the organs 
previously described but also the kidney. It causes monoclonal gammopathies of renal 
significance that leads from the development of a nephrotic syndrome to kidney 
failure. In 5% of patients, gastrointestinal deposits cause clinical manifestations of 
gastrointestinal malabsorption, and in 15% of patients the deposit is in the liver with 
the development of hepatomegaly/splenomegaly and different grades of organ 
dysfunction[2].
Classically, diagnosis of CA required pathological confirmation of amyloid 
deposition in the myocardium obtained through endomyocardial biopsy. However, 
thanks to the algorithm published in 2016 that joins the determination of monoclonal 
proteins in blood and urine together with the performance of a 99mTc-labeled 
phosphate scintigraphy, it is possible to perform the noninvasive diagnosis of patients 
with ATTR-CA[8,14]. Nowadays, different hospital protocols have adapted the algorithm 
published by an expert consensus in order to reduce the invasive approach (Figure 1).
CARDIAC IMAGING
Cardiac imaging is playing an increasingly important diagnostic and prognostic role in 
amyloidosis. It allows reducing the invasive approach thus decreasing the number of 
endomyocardial biopsies performed to confirm the diagnosis. In this review we 
analyze the different cardiac imaging tools.
ECHOCARDIOGRAPHY
Transthoracic echocardiography (TTE) is an accessible and harmless technique for the 
patients, so it is usually the first study performed to rule out cardiac involvement in 
amyloidosis.
As previously described, amyloid deposition causes thickening of both ventricles. 
The characteristic pattern was defined as concentric; however, in several studies 
different patterns such as the asymmetric septal were observed[15]. Multiple studies 
suggest that the measurement of 12 mm or more in the long parasternal axis at the 
level of the interventricular septum, in the absence of alternative causes of LVH, is the 
cut-off point for suspecting CA[16]. The appearance of the left ventricle (LV) wall has 
been classically described with the term “sparkling.” However, it is not diagnostic of 
CA because multiple situations can simulate this appearance.
Other findings that can be observed in CA are valve or interatrial septum 
thickening, biatrial dilatation and mild pericardial effusion. Valve involvement, 
objectified in the mitral and tricuspid valves in 50% of patients and in the aortic valve 
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Figure 1 Algorithm for diagnostic patients with suspected cardiac amyloidosis[78]. AL: Light chain amyloidosis; ATTR: Transthyretin amyloidosis; 
ATTRv: Variant transthyretin amyloidosis; ATTRwt: Wild-type transthyretin amyloidosis; CA: Cardiac amyloidosis; ECG: Electrocardiogram.
in 25%, has been related to a more advanced New York Heart Association functional 
class, lower left ventricular ejection fraction (LVEF) and was associated with reduced 
5-year survival[17].
At first, it is important to use conventional ultrasonography. It allows us to obtain a 
high suspicion of amyloidosis. With conventional TTE, there are parameters that guide 
the differentiation between CA and hypertrophic cardiomyopathy (HCM). For 
example, in HCM, LVH is usually severe and asymmetric, generating an obstructive 
gradient in the outflow tract. However in CA, LVH is usually concentric, not so severe, 
without an obstructive gradient and sometimes with sparkling. Likewise, interatrial, 
pericardial involvement and the apical sparing are usually rare in HCM unlike in 
CA[18].
Diastolic function is impaired and in the advanced stages it presents a restrictive 
filling pattern. The deceleration time of transmitral E wave, E/A ratio of transmitral 
flow and D/S ratio of pulmonary venous flow were independent predictors of overall 
death[19].
Functional assessment of the LV can be carried out in different ways. CA 
predominantly affects diastolic function; thus it was traditionally related to normal or 
slightly depressed LVEF values. However, it has recently been observed in different 
series that up to 50% of patients with ATTRwt-CA had LVEF < 50%[20]. Small variations 
in LVEF may imply large myocardial amyloid deposits. For this reason, other 
parameters have been evaluated to detect early alterations in the correct functioning of 
the LV with low cardiac amyloid burden. In AL-CA patients with normal LVEF but 
symptomatic and with high cardiac biomarker values, parameters such as stroke 
volume index < 33 mL/min, myocardial contraction fraction (MCF) (calculated as a 
ratio between LV stroke volume and LV myocardial volume) < 34% and cardiac-index 
< 2.4 L/min/m2 determine a higher mortality. Moreover, these measurements are 
altered before LVEF, so they provide earlier information[21]. Myocardial dysfunction 
from amyloidosis can prolong pre-ejection period leading to reduced ejection time, 
and its measurement has shown an important prognostic implication. The cut-off ≤ 240 
ms had a specificity of around 90% in predicting 1-year cardiac mortality in AL-CA 
patients[22,23].
Right ventricle (RV) involvement has been studied as a prognostic factor in the 
evolution of the disease. It was observed that a ventricular area ratio ≤ 2 predicts 
survival in AL-CA patients[24]. In both AL-CA and ATTR-CA, reductions in RV 
fractional shortening, tricuspid annular plane systolic excursion (TAPSE), tissue 
Doppler systolic velocity and global RV longitudinal strain have been described. Of 
them, only TAPSE < 14 independently predicted 6 mo major adverse cardiac events[25]. 
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Therefore, a simple technique such as measuring TAPSE is particularly useful in the 
prognostic evaluation of the disease.
Diastolic dysfunction progressively generates biatrial dilation, and it has been 
shown that patients with higher N-terminal pro b-type natriuretic peptide (NT-
proBNP) and troponin values presented larger indexed 3D left atrial volumes and 
lower 3D left atrial total emptying fraction. A cut-off of 3D left atrial total emptying 
fraction < 34% combined with worse 3D peak atrial longitudinal strain had 
significantly lower 2-year survival[26].
Longitudinal (LS) and radial strain total values are reduced in CA. Phelan et al[27] 
described the regional variations in LS from base to apex in CA patients. Patients with 
CA typically present a marked decrease in longitudinal strain in the basal and midwall 
segments and a relative apical sparing (Figure 2). The relative apical longitudinal 
strain [average apical longitudinal strain/(average basal + mid longitudinal strain)] 
greater than 1 could differentiate CA from hypertrophic cardiomyopathy and aortic 
stenosis with high diagnostic precision (sensitivity 93%, specificity 82%). Along the 
same lines, Koyama et al[28] showed that the reduction of LV basal strain was an 
independent predictor of both cardiac and overall deaths. Different articles published 
later, defined other relevant diagnostic and prognostic strain measurements. Speckle-
tracking-imaging derived global longitudinal early diastolic strain rate was superior to 
conventional diastolic parameters for predicting mortality in CA patients with 
preserved LVEF, increasing the risk of death fourfold with a cut-off value of 0.85[29]. RV 
strain analysis brings more prognostic information. Free-wall right ventricular 
longitudinal strain worse than 21.2% distinguishes between CA and other etiologies of 
cardiac hypertrophy[30].
LS and 2D-global LS provided incremental value to the combination of NT-proBNP, 
troponin and clinical parameters on survival in AL amyloidosis, and LS correlated 
strongly with the amyloid deposition measured histologically[31,32]. Strain is especially 
useful in early stages of the disease and could set up groups with a worse prognosis.
In summary, echocardiography can objectify cardiac infiltration in all its stages. The 
effect of strain and E/e’ have high probabilities of being abnormal at low cardiac 
amyloid burden. However, indexed stroke volume, MCF and TAPSE are abnormal 
more gradually with the progressive amyloid infiltration. Finally, at high levels of 
cardiac infiltration, biatrial areas and biventricular ejection fraction are altered[33]. 
Echocardiography is an important resource to objectify cardiac involvement. The 
advantages of the use of conventional TTE are: Rapid and instantaneous diagnostic 
tool; technically simple and easily interpretable; high availability; and does not require 
radiation of the patient. Completing the study with the strain test can slightly prolong 
the duration of the procedure, but it has a greater interpretive difficulty and the 
availability of the software is lower, which limits its use. The combination of structural 
parameters such as the biventricular hypertrophy pattern, biatrial dilation, pericardial 
effusion, interseptal and valve thickening associated with functional parameters such 
as conventional diastolic function measurement, MCF and the strain parameters allow 
clinicians to perform a first diagnostic approach and provide prognostic data on the 
evolution of the disease.
CARDIAC MAGNETIC RESONANCE
Cardiac magnetic resonance (CMR) is a widely used technique today. It is a 
noninvasive tool that permits the evaluation of cardiac structure and function as well 
as characterization of the composition of interstitial tissue. To this aim, certain 
sequences are used, and it can be grouped into three categories: Functional/cine 
imaging; Noncontrast tissue imaging; and Postcontrast tissue imaging[34].
Cine sequences or functional assessment in patients with CA allow visualizing the 
morphology of the infiltrated myocardium (i.e. biventricular hypertrophy, valvular or 
interatrial septum thickening, pericardial effusion or biatrial dilation) and accurately 
assessing systolic and diastolic function. It is particularly important for the evaluation 
of the LV and the rest of the cardiac chambers. RV involvement is a predictor of 
mortality in CMR, as it had been shown previously in TTE[35]. With the disease 
progression towards advanced stages, there is an increase in the atrium volume and an 
alteration of their functioning. It occurs by direct infiltration of the amyloid fibrils in 
the atrium and indirectly by the increase in filling pressures secondary to diastolic 
dysfunction. Mohty et al[36] observed in patients with AL-CA that the reduction of the 
total left atrial emptying fraction was not only related to more advanced stages of the 
disease and with a worse functional class but also with an increase in 2-year mortality 
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Figure 2 Transthoracic echocardiography imaging from a patient with transthyretin amyloidosis-cardiac amyloidosis. A: Strain imaging by 
transthoracic echocardiography; B: Reduced mid and basal values with apical sparing.
if its value decreased below 16%. In addition, the CMR also allows us to measure less 
frequently used parameters such as MCF and long axis strain. These new 
determinations can further stratify the risk in AL-CA patients with late gadolinium 
enhancement (LGE) uptake if the value of long axis strain exceeds 7% and the MCF 
value decreases below 52.6%. This subgroup of patients will have the greatest risk of 
death and heart transplantation[37].
Unlike TTE, CMR usually provides high image quality that allows differentiation of 
the endocardial border and greater definition of small displacements. Ochs et al[38] 
evaluated the prognostic value of different valve plane displacements. Traditionally, 
this measurement is reduced to TAPSE and inferoseptal mitral plane systolic 
excursion. However, it was found that the anterior aortic plane systolic excursion was 
the valve displacement that provided the best predictive value for transplant-free 
survival in AL patients. Therefore, cine sequences provide a global assessment with 
important prognostic and diagnostic information. It can even objectify the alteration of 
different parameters at low cardiac amyloid burden[39].
The strain can be analyzed by CMR to complete a deep study. Wan et al[40] noticed 
that the strain correlates well with the level of LGE uptake, and it may be an 
alternative to LGE in the group of patients where contrast should not be used 
(Table 1). They found that global longitudinal strain and global circumferential strain 
were significantly lower in the subendocardial and transmural than in no or 
nonspecific LGE group. They also found that the impaired global longitudinal strain 
was a robust predictor of all-cause mortality. Furthermore, they emphasized the utility 
of this tool in the early stage of the disease because in AL patients without cardiac 
involvement, basal segmental circumferential strain and radial strain were 
significantly impaired compared with those in healthy subjects.
One of the most worthwhile uses of CMR is the possibility of characterizing the 
tissue in a noninvasive way, for which the pre-contrast (native) T1 mapping, the 
postcontrast imaging-LGE and T1 mapping are used. In amyloidosis, the deposition of 
amyloid fibrils in the extracellular level causes an increase in the interstitial volume 
and a greater accumulation of gadolinium in that level.
The significant amyloid deposit alters the gadolinium kinetics. The gadolinium 
presents a rapid clearance from the intravascular space into the extracellular space. 
Thus the myocardial signal becomes hyperintense before the blood pool signal, unlike 
healthy patients. It is difficult to acquire and correctly interpret LGE images. 
Therefore, in the imaging acquisition of LGE the inversion time on the scanner needs 
to be adjusted to make the normal myocardium appear dark and the abnormal tissue 
bright. If the amyloid infiltration is diffusely distributed, then it is even more difficult 
to identify the optimal inversion time because of little or no normal tissue available to 
null the myocardium. There are some tools to overtake this issue like phase correction 
inversion recovery LGE imaging or quantitative T1 mapping. It has prognostic 
implications because there is an increased risk of death if it is impossible to obtain a 
normal myocardial signal on LGE using the look locker sequence (T1 sequence with 
different inversion times) with inversion time over 300 ms[41].
The typical pattern of LGE in amyloidosis is a diffuse subendocardial uptake, and it 
was described a transmural pattern enhancement and less frequently a focal patchy 
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Table 1 Early imaging tool for cardiac amyloidosis diagnosis
Patients with renal impairment Patients without renal impairment
TTE MCF, cardiac-index, strain parameters, E/A ratio of 
transmitral flow
MCF, cardiac-index, strain parameters, E/A ratio of 
transmitral flow
CMR Stroke volume index, global longitudinal and 
circumferential strain, T1 native
Stroke volume index, global longitudinal and circumferential 
strain, T1 native and ECV
CCT ECV
Nuclear imaging 99mTc-DPD myocardial uptake, MIBG uptake 
99mTc-DPD: 99mTc-labeled 3,3-diphosphono-1,2-propanodicarboxylic acid; CCT: Cardiac computed tomography; CMR: Cardiac magnetic resonance; ECV: 
Extracellular volume; MCF: Myocardial contraction fraction; MIBG: 123-iodine metaiodobenzylguanidine; TTE: Transthoracic echocardiography.
one. The gadolinium deposits usually involve the RV and the atrial walls. Controversy 
exists regarding the prognostic implication of gadolinium uptake in the myocardium. 
Maceira et al[42] noticed that the presence of LGE was not a robust predictor of death 
but they described a new method to measure gadolinium kinetics: The difference post-
gadolinium intramyocardial T1 between subepicardium and subendocardium. If there 
is less difference between the subepicardium uptake and the subendocardium uptake, 
it implies that the amyloid infiltration is more diffuse. These patients had a worse 
survival when that difference was lower than 23 ms. Ruberg et al[35] founded in 28 AL 
patients with suspected heart disease that the LGE is highly sensitive and specific (86% 
and 86% respectively) for the identification of CA, and it correlated with high values of 
brain natriuretic peptide but did not predict survival. A clear correlation with high 
NT-proBNP values and the extent of LGE was observed without showing a direct 
relationship with survival[43]. However, multiple subsequent studies demonstrated a 
relevant prognostic implication of LGE in this disease. Diffuse subendocardial uptake 
detected using a modified LGE-CMR protocol with visual T1 assessment had high 
diagnostic precision (positive predictive value 93%, negative predictive value 90%), 
and it was significantly associated with 2-year mortality[44,45]. Fontana et al[46] observed 
the presence of a transmural pattern in ATTR and AL patients that predicted high risk 
of death in a follow-up period of 24 + 13 mo.. All of this information was tested in a 
meta-analysis where it was found that in patients with known or suspected CA, LGE 
was associated with an odds ratio of 4.96 (95% confidence interval: 1.90 to 12.93) for 
all-cause mortality, without differences between both types of CA[47].
Wan et al[48] studied the RV gadolinium uptake in AL patients, and they showed that 
it was an independent predictor of survival during a period of 6 mo follow-up. 
Afterwards, the same investigation group[49] proposed a new CMR parameter, the 
query amyloid late enhancement score. It is a semiquantified measurement of LGE in 
both LV and RV, where higher values imply greater involvement. The query amyloid 
late enhancement score above 9 predicted worse survival, and it was especially useful 
in patients with a subendocardial LGE pattern because the query amyloid late 
enhancement score value above 9 defined a subgroup with a higher risk of death.
In patients with AL-CA, the diffuse pattern provides incremental prognosis over 
biomarker stage[50]. In patients with multiple myeloma the presence of LGE patterns 
included diffuse subendocardial, transmural and focal or patchy, and suboptimal 
nulling provides incremental prognosis for mortality prediction over biomarker stage, 
clinical and echocardiographic variables[51]. In patients with ATTR-CA, the presence of 
LGE increases the prognostic power over the functional New York Heart Association 
class[52]. This information suggests that the combination of conventional LGE images 
with clinical, biomarker and echocardiographic findings has an important prognostic 
role, and it improves the diagnostic accuracy in CA.
Noncontrast T1-mapping has the potential to detect and quantify cardiac 
involvement and could become a clinically useful diagnostic and prognostic tool, 
especially for impaired renal patients where the use of contrast has deleterious effects. 
The amyloid infiltration alters cardiac native signal. In ATTR and AL patients, it 
involves greater myocardial T1 native values. The increase of T1 values is not only due 
to interstitial expansion but also cellular hypertrophy. It could limit the ability of 
myocardial T1 values to distinguish CA from other cardiac hypertrophy etiologies, 
especially in early stages where there is little interstitial expansion[34]. Despite that, 
Karamitsos et al[53] proved that myocardial T1 was increased in AL amyloidosis even 
when cardiac involvement was uncertain or absent, showing that this tool could allow 
an early diagnosis of CA. The cut-off value of 1020 ms had high sensitivity and 
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specificity (around 90%) for identifying amyloid patients with possible or definite 
cardiac involvement. Higher T1 values were well correlated with decreased LVEF, 
decreased LV mass index and with worse diastolic function suggesting that T1 
changes could reflect more severe cardiac involvement. At that time, there was still no 
clear information about the prognostic implication of native T1.
T1 mapping (Figure 3) with native T1 and extracellular volume (ECV) are recently 
developed quantitative parameters. Patients with AL and suspected cardiac 
involvement had increased values of native T1 and ECV, even in early stages where no 
LGE was demonstrated[54]. It emphasized that native T1 and ECV are more useful tools 
than LGE in early cardiac diagnosis. However, only the ECV had a significant 
prognostic implication with greater mortality if its value was above 44%. This tool was 
especially useful in subgroups with the same LGE pattern where the ECV could 
distinguish a high risk group[54]. Basal, mild and apical level of native T1 and ECV 
were quantified in a Wan et al[55] report. Basal ECV had the best prognostic value 
amongst myocardial T1 mapping parameters, and it increased in patients without LGE 
uptake, strengthening the concept that this tool is very useful in early disease stages. 
Later, relative to ATTR-CA, Martinez-Naharro et al[56] observed that both native T1 and 
ECV provided excellent diagnostic accuracy for identification of ATTR-CA, without 
difference between the two types of ATTR. Similar to AL, only ECV was an 
independently predictor of mortality. Both native T1 and ECV correlated with cardiac 
function parameters and with increasing cardiac uptake (assessed by bone 
scintigraphy). They noticed that due to the different biological information provided 
by native T1 and ECV measurements (ECV measures extracellular volume and native 
T1 measures the interstitial expansion and the cellular hypertrophy) that there were 
discrepancies in measurements depending on the level of cardiac infiltration. When 
amyloid burden was moderate or severe, there were discrepancies between the results 
of ECV and native T1. However at low level infiltration assessed by nondiagnostic 99m
Tc-labeled 3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) grade 1 uptake, 
there were consistent abnormal values of both myocardial T1 and ECV, proving that 
they had greater precision at low amyloid burden. Using these measurements, CMR 
could detect a phenotype of early amyloid infiltration. Unless the patient had impaired 
renal function, the ECV was a better T1 mapping parameter than native T1[54].
Another sequence that it could be used in the diagnosis of CA is the T2-weighted 
imaging, and it is attractive because no gadolinium administration is needed. A 
decreased myocardial signal intensity compared with skeletal muscle in T2 images 
was associated with shortened survival. However, for a T2 ratio value less than 1.36 it 
had a weak sensitivity and specificity (63% and 73%, respectively) to predict cardiac 
involvement[57,58].
In conclusion, CMR would be a second step to complete the diagnostic study of a 
patient with suspected CA. It is an imaging technique that is not available in many 
hospitals, and the long duration of each study limits the number of studies that can be 
performed per day. Likewise, increasing the number of sequences further prolongs the 
duration of the test, which hinders accessibility. Another drawback is that it does not 
provide instant information as with TTE, and postprocessing is required to complete 
the entire test. However, the great advantage of this technique, in addition to the 
anatomical and functional cardiac characterization, is the tissue characterization and 
the absence of ionizing radiation on the patient. The use of contrast for gadolinium 
uptake sequences would cause kidney damage, but as previously exposed, it seems 
that the use of strain presents an adequate correlation with gadolinium uptake, which 
obviate this sequence in patients at risk of impaired kidney function. Therefore, the 
use of CMR establishes an early and accurate diagnostic approach in CA through 
measurement of MCF, strain parameters, native T1 and ECV. These measurements 
associated with an adequate assessment of the RV, atrial function and in non-
contraindicated cases the pattern of LGE uptake have shown implications in the 
prognosis and mortality of the patient. Therefore, it is a fundamental tool in the 
diagnosis of CA.
CARDIAC COMPUTED TOMOGRAPHY 
The usefulness of cardiac computed tomography (CCT) for the diagnosis of CA is 
unknown due to few trials. Nevertheless, it is commonly used to rule out the presence 
of other concomitant diseases. This tool, despite being more accessible than 
performing a CMR or a scintigraphy, has deleterious effects on the patient, such as the 
use of contrast and radiation exposure[34].
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Figure 3 Native T1-mapping images. Abnormally elevated values of T1 native (1120 ms) in a patient with amyloidosis-cardiac amyloidosis.
Few studies have been published about the diagnosis of CA by CCT. Treibel et al[59] 
compared a small sample of 26 patients with AL and ATTR-CA with patients with 
severe aortic stenosis by quantifying the contrast distribution in the extracellular 
volume by CCT. They underwent a dynamic equilibrium CCT protocol with rapid 
contrast administration to quantify the ECV. The authors observed an adequate 
correlation between the ECV measured by CCT in the first 5 min and the ECV 
measured by CMR, with high diagnostic accuracy of CA and a great correlation with 
clinical and biochemical markers of disease severity. Furthermore, CCT had good 
results and was easier, quicker and more accessible than CMR.
To quantify the ECV by CCT it is necessary to obtain a combination of the 
hematocrit, pre- and postcontrast measurements. Treibel et al[60] simplified this 
technique to not require blood extraction, further facilitating the use of this method.
Despite the disadvantages of this technique with respect to ionizing radiation and 
the need to use contrast, the greater availability of this tool and the capacity of tissue 
characterization with the ECV measurement, makes the CCT an alternative to CMR in 
the diagnosis of cardiac infiltration by amyloid.
NUCLEAR IMAGING 
None of the previous cardiac imaging tools gives us great information with regard to 
the type of CA. The main utility of the scintigraphy is to precisely differentiate the 
types of amyloidosis.
9 9 mTc-DPD, 9 9 mTc-labeled pyrophosphate (99mTc-PYP) and 9 9 mTc-labeled 
hydroxymethylene diphosphonate were the different bone avid radiotracers used for 
ATTR-CA diagnosis[14]. Fibril deposits are composed of the precursor protein, heparin 
sulfate proteoglycan and a calcium dependent P-component. It is thought that the use 
of calcium for binding amyloid P and fibrils explains the uptake of 99mTc-bone avid 
tracers. Stats et al[61] histologically showed that hearts affected by ATTR-CA have 
higher microcalcification density compared to hearts with AL-CA, which may explain 
the higher uptake in the ATTR subgroup. This binding allows a semiquantitative 
(visual) scoring and a quantitative (heart to contralateral ratio) assessment of amyloid 
protein deposition.
The use of 99mTc-labeled hydroxymethylene diphosphonate allows us to distinguish 
cardiac involvement by transthyretin from other nonamyloid left ventricle 
hypertrophy, and it predicts acute heart failure and/or death[62]. However, the ability 
to differentiate between the two subtypes is limited, and its diagnostic utility 
compared to 99mTc-PYP and DPD is likely suboptimal.
In Europe, 99mTc-DPD is the only radiotracer approved for clinical use. Perugini 
et al[63] documented the high accuracy (around 100%) of 99mTc-DPD scintigraphy for 
distinction of AL and ATTR etiology (Figure 4). Subsequently, in patients with ATTR-
CA, the 99mTc-DPD myocardial uptake proved to be a determinant of cardiac outcome, 
and it could also detect the myocardial involvement before visualization of 
morphological abnormalities by echocardiogram, which is very relevant in the early 
diagnosis of CA[64]. Regarding the different degrees of uptake in the semiquantitative 
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Figure 4  Planar scintigraphy showing intense cardiac uptake of 99mTc-labeled 3,3-diphosphono-1,2-propanodicarboxylic acid 
corresponding to a grade 3 in a patient diagnosed with cardiac amyloidosis-transthyretin amyloidosis.
measurement of the uptake of 99mTc-DPD, Hutt et al[65] showed a better survival in 
patients with grade 0 compared to grades 1, 2 and 3 with no differences in nonzero 
degrees.
99mTc-PYP is the other tracer available in North America. Bokhari et al[66] proved that 
patients with ATTR-CA had a significantly higher uptake of 99mTc-PYP than AL-CA 
patients evaluated both semiquantitatively and quantitatively, and the elevated 
cardiac uptake was associated with an increase of all-cause mortality[14]. The heart to 
contralateral ratio > 1.5 had a sensitivity of 97% and a specificity of 100% for the 
diagnosis of ATTR-CA. In a period of 5 years, a heart to contralateral ratio of 1.6 or 
greater was associated with a significantly worse survival[67]. In relation to this tracer, 
Sperry et al[68] described an apical-sparing pattern and an increase in mortality 
dependent on regional distribution of LV 99mTc-PYP uptake. Patients with diffuse 
infiltration had more apical uptake and as a result a worse survival.
Gillmore et al[14] studied the uptake of these radiotracers in patients with suspected 
CA, and they found that a visual scoring of a radiotracer uptake grade ≥ 2 without 
monoclonal proteins on serum and urine analysis had a specificity and positive 
predictive value of 100% for ATTR-CA. As we explained previously, this information 
revolutionized the noninvasive diagnosis of CA, avoiding a large number of invasive 
procedures in these patients.
Positron emission tomography tracers are being investigated for the diagnosis of 
CA. The advantage over single-photon emission computed tomography tracers is that 
they allow quantification of the amyloid burden. To date the different tracers 
evaluated are 18F-florbetapir, 18F-florbetaben and 11C-Pittsburgh Compound-B in 
which a higher uptake has been observed in patients with amyloidosis compared to 
other types of cardiomyopathies. Regarding 18F-florbetapir the retention index and 
the uptake values in the LV myocardium was greater in patients with amyloidosis, 
and higher values have been observed in AL compared to ATTR hearts without 
significant differences[69]. Likewise, the increased uptake correlated with deterioration 
of biventricular function[70]. However, its prognostic involvement in the survival of 
these patients has not yet been demonstrated in multicenter studies, and it is a future 
research field.
In patients with amyloidosis, myocardial sympathetic denervation often precedes 
the neurological and cardiac manifestations, especially in ATTRv. Therefore, the 
detection of this situation could anticipate cardiac involvement[71]. 123-iodine 
metaiodobenzylguanidine (MIBG) imaging assesses myocardial sympathetic 
denervation, and the reduction of the myocardial uptake previously occurs before 
morphologic alterations visualized by TTE. An increased 5-year mortality rate in 
ATTR patients with a heart to mediastinum MIBG uptake ratio below 1.6[72] and worse 
liver transplant survival outcomes in ATTRv with a ratio lower than 1.43[73] has been 
observed. Even, cardiac sympathetic denervation documented by decreased MIBG 
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uptake is detected earlier than amyloid burden demonstrated by 99mTc-DPD 
scintigraphy in ATTRv patients, highlighting the importance of this tool for an early 
diagnosis in this subgroup of patients[74].
The disadvantage of scintigraphy, as well as CCT, is that it requires exposure to 
ionizing radiation. Advantages of this tool are the early diagnosis, even before the 
anatomical alterations are evident, and the ability to distinguish the different types of 
amyloidosis. Due to the advances in this technique, an algorithm has been developed 
that allows the diagnosis of ATTR-CA without the need for endomyocardial biopsy. 
Currently, it has positioned itself as one of the imaging techniques that contributes the 
most in the precise diagnosis of ATTR-CA.
MACHINE LEARNING
Before ending this review, we want to highlight the growth of machine learning and 
artificial intelligence in medicine in general and in diagnostic imaging in particular. It 
consists of using algorithms that learn from previous studies, identifying complex 
image patterns and later apply them in the diagnosis of different pathologies. In this 
way, we can shorten the duration of the different imaging techniques and increase 
diagnostic precision by reducing the interobserver variability of the tests[75,76].
The machine learning-based radiomics technique has been studied in different 
imaging tools (TTE, CCT, CMR and scintigraphy) with high diagnostic precision in 
acute myocardial infarction, HCM and RV abnormalities. However, the data about its 
applicability in the diagnosis of CA are limited. There was a study conducted by 
Zhang et al[77] that used automated cardiac image interpretation in patients diagnosed 
with CA. They evaluated myocardial structure, ventricular function and LS measured 
by TTE and compared it with segmentation and manual measurement. Using the cases 
with confirmed CA and matched controls, they found high diagnostic precision with 
an area under the curve of 0.87 (95% confidence interval: 0.83–0.91). It provides 
promising data that could revolutionize routine clinical practice. However, to 
implement the use of machine learning in CA, it is necessary to obtain more data about 
the diagnostic precision of the other imaging techniques as well as several studies to 
evaluate the ability of this technique to distinguish different cardiomyopathies.
CONCLUSION
Advances in cardiac imaging techniques not only allow for an accurate and early 
diagnosis, but also provides relevant prognostic information of patients. Given a 
clinical suspicion of cardiac involvement due to amyloidosis, initially an 
approximation study should be performed using TTE because it is the fastest and 
safest technique. TTE should evaluate simple measurements, such as TAPSE, whose 
alterations are relevant to patient mortality. Likewise, more complex measurements 
should be studied such as strain and MCF. They are altered in patients with low levels 
of myocardial infiltration, and it could modify their prognosis with the early 
establishment of treatment.
Subsequently, depending on the availability of the hospital, it would be advisable to 
perform a tissue characterization through CMR or CCT. The use of native T1 and ECV 
have a high diagnostic precision for CA and their alteration have already been 
observed in early stages of the disease. If renal function allows, then the use of the LGE 
imaging provides additional information on the prognosis, although it could be 
substituted for the strain analysis.
The noninvasive differentiation of amyloidosis types can be carried out with high 
precision through the 99mTc-DPD scintigraphy, and the detection of sympathetic 
denervation with decreased MIBG uptake anticipates the diagnosis of cardiac 
infiltration even before 99mTc-DPD myocardial uptake.
Finally, we hypothesize that cardiac imaging could replace invasive techniques in 
the CA diagnosis. Depending on the accessibility to the imaging techniques in the 
different hospital centers, multiple measurements with important prognostic 
implications in these patients can be selected.
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